Medical Facilities (DR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 Mar, 2026Executive summary
Achieved strong Q4 and full-year growth in facility service revenue, income from operations, and adjusted EBITDA, driven by higher case volumes and favorable case and payer mixes.
Facility service revenue grew 3.2% year-over-year to $342.2 million, with Q4 revenue up 6.9% to $97.3 million.
Income from operations increased 6.1% to $58 million for the year, with a 20.1% rise in Q4 to $20.9 million.
Adjusted EBITDA rose 3.1% to $73.7 million for the year, with 12% growth in Q4 to $24.4 million.
Completed significant shareholder returns through share repurchases and asset sales, reducing share count by 22%.
Financial highlights
Full-year revenue grew 3.2% to $342.2 million; Q4 revenue up 6.9%.
Q4 facility service revenue from continuing operations increased 8.6% year-over-year to $75.1 million.
Net income from continuing operations was $34.6 million for the year, down 28.3% year-over-year.
Q4 Adjusted EBITDA from continuing and selected discontinued operations was $24.4 million, up 12.0%.
Annual dividend of C$0.36 per share, yielding 2.27% on year-end share price.
Outlook and guidance
Monitoring site neutrality legislation and Medicare policy changes, with no current impact but ongoing evaluation.
Evaluating use of net proceeds from asset sales, including further share repurchases or distributions to shareholders.
Exploring further capital returns to shareholders via share repurchases, substantial issuer bids, or special distributions.
Latest events from Medical Facilities
- Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 20242 Feb 2026 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 202416 Jan 2026 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 202426 Dec 2025 - Revenue and EBITDA stable, net income up, and $44.3M returned to shareholders via buybacks.DR
Q1 202525 Nov 2025 - Q2 saw SFSH headwinds but strong net income growth and new $40M credit secured.DR
Q2 202523 Nov 2025 - 7.5% revenue growth, 10.2% higher EBITDA, and $5.6M in share buybacks in Q3 2025.DR
Q3 202513 Nov 2025